This second day play has massive potential 🚀

Good day, 360 –

Here are our top 3 trade ideas today – these setups look primed! And don't forget to check out our Economic Calendar below. Be the best prepared trader on the Street!

XPON - 2nd day play. Closed up 50% after announcing it would be exclusive supplier of lithium-ion batteries for Cube Series camper

CLNN - Trades 70% higher in pre-market after Phase 2 success in Multiple Sclerosis study

FSLY - B of A Securities upgrades Fastly to Buy, raises price target from $10.50 to $16

XPON - 2nd day play. Closed up 50% after announcing it would be exclusive supplier of lithium-ion batteries for Cube Series camper

Expion 360 (XPON) announced it would be the exclusive supplier of lithium-ion batteries for an ultra-lightweight foldable camper made by Cube Series.

Cube Series campers are compatible with trucks such as Rivian. XPON opened on its IPO day around $8 and was trading at $2 before the news. It closed yesterday at $3.08 on volume of over 60 million shares and is gapping another 20% higher this morning.

According to Finviz, the stock only has a float of 3.34 million shares, so traded almost 20 times the float on Friday. With a market cap of only $13.61 million at yesterday’s close, there is plenty of potential for this company to be revalued in the short-term.

Friday’s high of $3.75 should prove to be an important inflection point today. XPON has failed there on 3 occasions since December.

Above it the first target will be the pre-market high of $3.94. A break of $4 puts $4.50, then $5 and $5.30 in play above that. Given the small float and extreme volume there is no telling how high this can go if it catches.

Below $3.75 there is potential support at $3.08 which would be a gap fill. The next target would be $2.85 and $2.50 below that. This move began at $2.

Clene (CLNN) today announced updated MRI results from the Phase 2 double-blinded, 48-week treatment period of the VISIONARY-MS trial in multiple sclerosis (MS) patients. These exploratory MRI results:

• reinforced the clinical neurological improvements previously reported

• showed improved brain neuronal structural integrity, independent of an immunomodulatory effect

• showed decreased brain deterioration

The brain improvements in stable MS patients on background therapy appear unprecedented.

CLNN was trading above $10 back in 2021.

The first target for bulls is the pre-market high of $2.43.

Above that there is a gap to fill at $2.80. The next major resistance level above that is $3.19 with $3.50 and $3.80 above that.

Below $2.43 there is potential support at $1.90, then $1.70 and a gap to fill at $1.34.

FSLY - B of A Securities upgrades Fastly to Buy, raises price target from $10.50 to $16

Bank of America has a huge investor base, both retail and institutional so upgrades should be taken note of. B of A Securities upgraded FSLY from Underperform to Buy, raising the price target to $16.

FSLY is now on millions of investors' radars, and this could introduce new order flow. FSLY is gapping 8% higher this morning on the upgrade. Given the price target is more than 50% higher than current prices there is plenty of upside in the name and the potential for a trend day.

$10.80 was the pre-market high and should be an important pivot level today.

$11 was a major prior resistance area, with $11.50 and $12 the next targets above that.

Below $10.80, there is potential support at the $10.14-$10.10 area with a gap to fill at $9.87 below that.

Economic Calendar (EST)

11:30am 3-6 Month Bill Auction

Remember Tuesday at 8:30am is CPI numbers.

Earnings for Today (After Market)

ACGL, AEMD, AIN, AMKR, ANET, ANGI, ARKR, BLKB, BRX, CAR, CDNS, CGRN, DENN, ES, FE, IAC, ICMB, IFS,INST, KRG, LSCC, MEDP, MKSI, MRC, NOTV, NTB, OM, OTTR, PLTR, QIPT, RBOT, SEDG, SEVN, SKYT, VNO

Top Headlines

META has delayed finalizing multiple teams’ budgets while it prepares a fresh round of job cuts.

RGNX: REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

BGRY: Berkshire Grey Inc. (Nasdaq: BGRY), (“Berkshire Grey” or the “Company”), a leader in AI-enabled robotic solutions that automate supply chain processes, today confirmed that it has received a non-binding indication of interest from SoftBank Group Corp. (“SoftBank”) to acquire all the outstanding capital stock of the Company for $1.30 per share in cash.

GTHX: G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

AULT: Ault Alliance Announces Record Preliminary 2022 Revenue of $134 Million, up 156% from 2021

LEV: Lion Electric Announces North American Agreement with Mitsubishi HC Capital Canada and ENGS Commercial Finance Co. to Provide Financing for All-electric Buses and Medium- and Heavy-Duty Trucks Through LionCapital Solutions

NRXP: NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

ZG: Evercore ISI upgrades Zillow Group, says real estate stock could jump 40% on a 'rapid recovery' in the housing market – CNBC

HOOK: HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers

CLNN: Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

TNXP: Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

TLRY: Good Supply Cannabis Brand Launches New Product Lineup

HILS: Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer

IRWD: Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

GRCL: Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

PRVB: Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US

PHIO: Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

DGX: Cleveland Diagnostics Announces Agreement with Quest Diagnostics to Expand Patient Access to IsoPSA® Prostate Cancer Testing

ANPC: AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S.

NVAX: U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

SEEL: Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

MDRX: Veradigm and HealthVerity Collaborate to Advance Real-World Evidence and Care for Patients with Cardiovascular Disease and Diabetes

EXEL: Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

OCUP: Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

COMS: COMSovereign Announces an 80% Year-Over-Year Reduction of Outstanding Secured Debt

AUID: authID® Expands Verified™ CloudConnect™ to BeyondTrust, Bringing Unphishable Human Factor Authentication™ to Privileged Access Management

MAIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition

ABOS: Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

CRL: Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein

To Your Success!

*Please see disclosures below.

62 Calef Hwy #233 Lee, New Hampshire 03861 United States

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions